Introduction Cyclooxygenase-2 overexpression may mediate resistance to epidermal growth
factor receptor tyrosine kinase inhibition through prostaglandin E2-dependent promotion of …

Abstract Purpose: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …

Increasing evidence has suggested that high expression level of cyclooxygenase-2 (Cox-2)
is associated with the malignancies of non–small cell lung cancer (NSCLC), leading to a …

BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …

Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …

Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …

Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …

AIM OF THE STUDY: The primary purpose of this study is to investigate if pretreatment
plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of …

PURPOSE The selection of effective schedules of treatment for metastatic non-small cell
lung cancer still remains a challenge for the oncologist. The present multicentric phase II …

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …